⏳ Fetching live dividend data...
Home › Calculator › CYAD Dividend Calculator 2026
Celyad Oncology S.A. · NASDAQ
Price: $0.47 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
CYAD is not a dividend-focused stock
CYAD pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Celyad Oncology S.A. (CYAD) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer. Another allogeneic, shRNA-based CAR-T candidate, CYAD-211, is in Phase 1 for individuals suffering from relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T therapy, is being evaluated in Phase 1 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, Celyad is developing CYAD-203. This is a non-gene edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 (IL-18) alongside natural killer group 2D ligands (NKG2D), targeting solid tumors. Celyad has also forged strategic alliances. It holds a licensing agreement with Novartis International AG concerning US patents for allogeneic CAR-T cell technology. Furthermore, the company has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to establish a second non-gene-edited allogeneic platform. Founded in 2004, the company was initially named Celyad SA, but rebranded to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
No. Celyad Oncology S.A. (CYAD) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. CYAD has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CYAD position with:
Real after-tax yield depends on where you live and how you hold CYAD.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CYAD pays quarterly — 4 times per year. Ex-div: —.
How CYAD compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CYAD sourced from FMP /financial-growth endpoint — real data, not estimates.
Compare CYAD with peers: CYAD vs ATON · CYAD vs AXLA · CYAD vs GLS
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CYAD dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Celyad Oncology S.A. (CYAD) is currently trading at $0.47, 85% below its 52-week high. It does not currently pay a regular dividend.
Celyad Oncology S.A. (CYAD) is a healthcare stock trading at $0.47. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever